First Hospital of Shijiazhuang City
15
6
7
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
China Cognition and Aging Study
Role: collaborator
The Chinese Familial Alzheimer's Network
Role: collaborator
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
Role: collaborator
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Role: collaborator
Radiomics-Based AI Model for Predicting Para-Aortic Lymph Node Metastasis in Gastric Cancer Patients
Role: collaborator
Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma
Role: collaborator
Exploring the Diagnostic Biomarkers of Cognitive Disorders in China
Role: collaborator
Trabeculectomy Versus Peripheral Iridectomy Plus Goniotomy in Advanced PACG
Role: collaborator
Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China
Role: collaborator
Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer
Role: collaborator
Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer
Role: lead
Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
Role: lead
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
Role: lead
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Role: lead
Evaluation of Radiation Exposure and Risk Factors During Coronary Angiography
Role: collaborator
All 15 trials loaded